'Monoclonal Antibody Treatment' Helps Reduce Severe Risks of COVID-19, But Why is the FDA Reserving it to Specific People? The Monoclonal Antibody Treatment speaks of a high recovery rate for COVID-19, but the FDA is holding it up for specific reasons. by Isaiah Richard